Expression of p19(INK4d), CDK4, CDK6 in glioblastoma multiforme

British Journal of Neurosurgery

Volumn 14, Issue 1, 2000, Pages 28-32

  Lam, P Y P ^a   Ditomaso, E ^a   Ng, H K ^a,c   Pang, J C S ^a   Roussel, M F ^b   Hjelm, N M ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

CDK4; CDK6; Cell cycle; Glioblastoma multiforme; p19(INK4d)

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; CARRIER PROTEIN; CDK6 PROTEIN, HUMAN; CDKN2D PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 2D; PROTEIN P16INK4A; PROTEIN SERINE THREONINE KINASE; TUMOR PROTEIN;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CHROMOSOME 19P; CONTROLLED STUDY; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; CELL CULTURE; CENTRAL NERVOUS SYSTEM TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; WESTERN BLOTTING;

BLOTTING, WESTERN; CARRIER PROTEINS; CELL CYCLE PROTEINS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CYCLIN-DEPENDENT KINASE 6; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P19; CYCLIN-DEPENDENT KINASES; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; NEOPLASM PROTEINS; PROTEIN-SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED;

EID: 0034135920     PISSN: 02688697     EISSN: None     Source Type: Journal    
DOI: 10.1080/02688690042870     Document Type: Article

References (32)

1. 1 Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-12.
2. 2 Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-7.
3. 3 Hannon GJ, Beach D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 1994;371:257-61.
4. 4 Guan KL, Jenkins CW, Li Y, Nichols MA, Wu X, O'Keefe CL, Matera AG, Xiong Y. Growth suppression by p18, a p16INK4/MTS1 - and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 1994;8:2939-52.
5. 5 Hirai H, Roussel MF, Kato JY, Ashmun RA, Sherr CJ. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol 1995;15:2672-81.
6. 6 Chan FKM, Zhang J, Chen L, Shapiro DN, Winto A. Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16INK4. Mol Cell Biol 1995;15:2682-8.
7. 7 Schmidt EE, Ichimura K, Reifenberger G, Collins VP. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 1994;54:6321-4.
8. 8 Fueyo J, Gomez-Manzano C, Bruner JM, SaitoY, Zhang B, Zhang W, Levin VA,Yung WK, Kyritsis AP. Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas. Oncogene 1996;13:1615-19.
9. 9 Kyritsis AP, Zhang B, Zhang W, Xiao M,Takeshima H, Bondy ML, Cunningham JE, Levin VA, Bruner J. Mutations of the p16 gene in gliomas. Oncogene 1996; 12:63-7.
10. 10 He J, Alien JR, Collins VP, Allalunis-Turner MJ, Godbout R, Day RS III, James CD. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res 1994;54:5804-7.
11. 11 Biernat W, Tohma Y, Yonekawa Y, Kleihues P, Ohgaki H. Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta Neuropathol Biol 1997;94:303-9.
12. 12 Ichimura K, Schmidt EE, Goike HM and Collins VP. Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 1996;13:1065-72.
13. 13 Okuda T, Hirai H, Valentine VA, Shurtleff SA, Kidd VJ, Lahti JM, Sherr CJ, Downing JR. Molecular cloning, expression pattern, and chromosomal localization of human CDK2D/INK4d, an inhibitor of cyclin D-dependent kinases. Genomics 1995;29: 623-30.
14. 14 Zindy F, Soares H, Herzog KH, Morgan J, Sherr CJ, Roussel MF. Expression of INK4 inhibitors of cyclin D-dependent kinases during mouse brain development. Cell Growth Differ 1997;8:1139-50.
15. 15 von Deimling A, Louis DN, von Ammon K, Petersen I, Wiestler OD, Seizinger BR. Evidence for a tumour suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. Cancer Res 1992; 52:4277-9.
16. 16 von Deimling A, Nagel J, Bender B, Lenartz D, Schramm J, Louis DN, Wiestler OD. Deletion mapping of chromosome 19 in human gliomas. Int J Cancer 1994; 57:676-80.
17. 17 Ritland SR, Ganju V, Jenkins RB. Region-specific loss of heterozygosity on chromosome 19 is related to the morphologic type of human glioma. Genes Chromosomes Cancer 1995;12:277-82.
18. 18 Li YJ, Hoang-Xuan K, Delattre JY, Poisson M, Thomas G, Hamelin R. Frequent loss of heterozygosity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p15 (MTS2) and p16 (MTS1) genes in gliomas. Oncogene 1995;11:597-600.
19. 19 Barker FG, Chen P, Furman F, Aldape KD, Edwards MS, Israel MA. p16 deletion and mutation analysis in human brain tumours. J Neurooncol 1997;31:17-23.
20. 20 Schmidt EE, Ichimura K; Messerle KR, Goike HM, Collins VP. Infrequent methylation of CDKN2A (MTS1/p16) and rare mutation of both CDKN2A and CDKN2B (MTS2/p15) in primary astrocytic tumours. Br J Cancer 1997;75:2-8.
21. 21 Arap W, Knudsen E, Sewell DA, Sidransky D, Wang JY, Huang HJ, Cavenee WK. Functional analysis of wildtype and malignant glioma derived CDK2A beta alleles: evidence for an RB-independent growth suppressive pathway. Oncogene 1997; 15:2013-20.
22. 22 Burns KL, Ueki K, Jhung SL, Koh J, Louis DN. Molecular genetic correlates of p16, CDK4, and pRb immunohistochemistry in glioblastomas. J Neuropathol Exp Neurol 1998;57:122-30.
23. INK4a/MTS1, p18 and p19 in human cancer cell lines. Int J Cancer 1996;68:605-11.
24. INK4d, in tumour-derived cell lines and primary tumours. Oncogene 1996;13: 2033-8.
25. INK4d cyclin dependent kinase inhibitor gene is altered in osteosarcoma. Oncogene 1997;15: 231-5.
26. 26 Shiohara M, Spirin K, Said JW, et al. Alterations of the cyclin-dependent kinase inhibitor p19 (INK4D) is rare in hematopoietic malignancies. Leukemia 1996; 10:1897-900.
27. 27 Latham KM, Eastman SW, Wong A, Hinds PW. Inhibition of p53-mediated growth arrest by overexpression of cyclin-dependent kinases. Mol Cell Biol 1996; 16: 4445-55.
28. 28 Ohgaki H, Schauble B, zur Hausen A, von Ammon K, Kleihues P. Genetic alterations associated with the evolution and progression of astrocytic brain tumours. Virchows Arch 1995;427:113-18.
29. 29 Rollbrocker B, Waha A, Louis DN, Wiestier OD, von Deimling A. Amplification of the cyclin-dependent kinase 4 (CDK4) gene is associated with high CDK4 protein levels in glioblastoma multiforme. Acta Neuropathol (Biol) 1996;92:70-4.
30. 30 Costello JF, Plass C, Arap W, Chapman VM, Held WA, Berger MS, Su Huang H-J, Cavenee WK. Cyclindependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. Cancer Res 1997;57:1250-4.
31. 31 Holland EC, Hively WP, Gallo V, Varmus HE. Modeling mutations in the G1 arrest pathway in human gliomas: overexpression of CDK4 but not loss of INK4a-ARF induces hyperploidy in cultured mouse astrocytes. Genes Dev 1998;12:3644-9.
32. 32 Holland EC, Hively WP, DePinho RA, Varmus HE. A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev 1998; 12:3675-85.